Hospital
ST Joseph Mercy Hospital-Smhc
ST Joseph Mercy Hospital-Smhc was paid $51.85M by Medicaid between Jan 2018 and Dec 2024, across 444 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoST JOSEPH MERCY HOSPITAL-SMHC
PONTIAC, MI 48341
PONTIAC, MI 48341
33aNPI1053356352assigned 06/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$51.85M
24GClaims1,880,143
24DCodes billed444
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#23 of 86
Median peer was paid$21.55M
This provider vs. median2.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official GUSHO, MICHAEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 174,410 | $6.03M | |
| 2019 | 277,377 | $6.65M | |
| 2020 | 234,565 | $6.04M | |
| 2021 | 313,008 | $8.83M | |
| 2022 | 305,378 | $8.47M | |
| 2023 | 320,046 | $8.56M | |
| 2024incomplete | 255,359 | $7.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 36,585 | 33,936 | $9.38M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 19,497 | 18,218 | $8.21M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 54,212 | 50,261 | $7.15M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.1% | 35,815 | 32,314 | $3.18M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.2% | 30,256 | 28,898 | $2.20M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.1% | 24,444 | 18,636 | $1.59M |
| 80061 | Lipid panel | 1.7% | 31,798 | 31,589 | $875K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.5% | 9,803 | 9,590 | $779K |
| 76818 | 1.4% | 12,456 | 5,349 | $751K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 27,415 | 22,106 | $742K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.2% | 5,417 | 5,376 | $616K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 5,226 | 5,124 | $614K |
432 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 18,040 | $601K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 11,675 | $556K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 6,588 | $505K |
| G0378 | Hospital observation service, per hour | <1% | 14,434 | $478K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,723 | $466K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 9,585 | $407K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 11,943 | $389K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 15,626 | $346K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 19,193 | $320K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 20,269 | $319K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 19,057 | $314K |
| 59025 | Fetal non-stress test | <1% | 3,387 | $311K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,375 | $301K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 34,656 | $294K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 10,213 | $292K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,959 | $291K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,014 | $286K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,132 | $285K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,000 | $281K |
| 82947 | <1% | 8,228 | $258K | |
| 93975 | <1% | 2,261 | $252K | |
| 80053 | Comprehensive metabolic panel | <1% | 54,472 | $228K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,119 | $219K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,375 | $215K |
| 76830 | Ultrasound, transvaginal | <1% | 3,860 | $211K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 96,897 | $205K |
| 76801 | <1% | 3,251 | $188K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 9,882 | $179K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 11,939 | $174K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,437 | $171K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 18,507 | $160K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,400 | $149K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 681 | $146K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,397 | $143K |
| 97161 | <1% | 2,137 | $138K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,507 | $135K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 26,249 | $131K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,624 | $128K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,480 | $121K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 7,540 | $117K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,717 | $109K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,061 | $107K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 1,108 | $99K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,505 | $97K |
| 93971 | <1% | 1,946 | $96K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 25,013 | $94K |
| 76642 | <1% | 2,473 | $92K | |
| 70496 | <1% | 1,019 | $89K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 4,484 | $87K |
| 87480 | <1% | 11,651 | $85K | |
| 87660 | <1% | 11,576 | $84K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,338 | $82K |
| 88142 | <1% | 7,413 | $80K | |
| 76770 | <1% | 1,683 | $80K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 5,248 | $79K |
| 47562 | <1% | 24 | $75K | |
| 87510 | <1% | 10,965 | $74K | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 7,144 | $74K |
| 76536 | <1% | 1,411 | $70K | |
| 86900 | <1% | 10,473 | $68K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,949 | $68K |
| 72141 | <1% | 482 | $68K | |
| 82607 | <1% | 8,947 | $66K | |
| 84439 | <1% | 15,196 | $66K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,976 | $65K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 47,350 | $62K |
| 10060 | <1% | 728 | $62K | |
| 85027 | <1% | 35,537 | $60K | |
| 86003 | <1% | 1,627 | $60K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,061 | $60K |
| 82728 | <1% | 8,089 | $56K | |
| 86803 | <1% | 7,121 | $54K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 1,819 | $54K |
| 77066 | Tomosynthesis, mammo | <1% | 940 | $52K |
| 72110 | <1% | 1,635 | $52K | |
| 72100 | <1% | 1,668 | $50K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,349 | $49K |
| 93970 | <1% | 620 | $49K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,864 | $48K |
| 88342 | <1% | 1,482 | $47K | |
| 76825 | <1% | 193 | $46K | |
| 86780 | <1% | 4,857 | $45K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,682 | $45K |
| 71271 | <1% | 790 | $44K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 527 | $43K |
| 84702 | <1% | 10,896 | $40K | |
| 80074 | <1% | 1,704 | $38K | |
| 84481 | <1% | 4,061 | $37K | |
| 77065 | Tomosynthesis, mammo | <1% | 854 | $36K |
| 36415 | Collection of venous blood by venipuncture | <1% | 61,050 | $34K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 111 | $32K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,526 | $32K |
| 87340 | <1% | 6,910 | $30K | |
| 83970 | <1% | 1,456 | $30K | |
| 83655 | <1% | 4,118 | $28K | |
| 72131 | <1% | 699 | $28K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 41 | $28K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 2,746 | $27K |
| 87081 | <1% | 11,247 | $27K | |
| 84466 | <1% | 3,686 | $27K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,690 | $26K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,560 | $26K |
| 71250 | <1% | 561 | $25K | |
| 82746 | <1% | 3,466 | $24K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 15 | $24K |
| 83540 | <1% | 6,954 | $23K | |
| 70486 | <1% | 831 | $23K | |
| 0002A | <1% | 643 | $21K | |
| 93017 | <1% | 1,368 | $21K | |
| 96367 | <1% | 679 | $21K | |
| 84403 | <1% | 1,631 | $20K | |
| 83735 | <1% | 29,516 | $20K | |
| 73030 | <1% | 2,259 | $19K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,933 | $19K |
| 36430 | <1% | 130 | $19K | |
| 73562 | <1% | 1,682 | $19K | |
| 72050 | <1% | 523 | $19K | |
| 82105 | <1% | 2,258 | $19K | |
| 0001A | <1% | 673 | $18K | |
| 86762 | <1% | 3,296 | $18K | |
| 87077 | <1% | 5,682 | $17K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,355 | $17K |
| 86850 | <1% | 9,674 | $17K | |
| 82565 | <1% | 10,716 | $17K | |
| 81001 | <1% | 39,324 | $17K | |
| 77080 | <1% | 296 | $17K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,418 | $17K |
| 76813 | <1% | 1,639 | $16K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 138 | $16K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 686 | $16K |
| 73564 | <1% | 995 | $16K | |
| 87070 | <1% | 4,000 | $15K | |
| 82570 | <1% | 5,978 | $15K | |
| 83001 | <1% | 1,432 | $15K | |
| 73630 | <1% | 2,614 | $15K | |
| 82043 | <1% | 4,311 | $15K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 55 | $15K |
| 83880 | <1% | 4,514 | $14K | |
| 84460 | <1% | 10,816 | $14K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 51 | $14K |
| 84450 | <1% | 10,547 | $13K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 121 | $13K |
| 87186 | <1% | 4,210 | $13K | |
| 73610 | <1% | 2,156 | $13K | |
| 97162 | <1% | 109 | $13K | |
| 82670 | <1% | 820 | $13K | |
| 73130 | <1% | 2,627 | $13K | |
| 97165 | <1% | 240 | $12K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,673 | $12K |
| 86769 | <1% | 657 | $12K | |
| 82784 | <1% | 1,352 | $12K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,947 | $12K |
| 84146 | <1% | 1,112 | $11K | |
| 86235 | <1% | 216 | $11K | |
| 83002 | <1% | 1,051 | $11K | |
| 85610 | <1% | 12,444 | $11K | |
| 74018 | <1% | 1,337 | $10K | |
| 82785 | <1% | 1,132 | $10K | |
| 73502 | <1% | 1,096 | $10K | |
| 83550 | <1% | 2,561 | $10K | |
| 82465 | <1% | 1,449 | $10K | |
| 88304 | <1% | 1,668 | $10K | |
| 80051 | <1% | 6,311 | $9K | |
| 73110 | <1% | 1,396 | $9K | |
| 86592 | <1% | 3,459 | $9K | |
| 87147 | <1% | 3,241 | $9K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 23,582 | $9K |
| 84520 | <1% | 10,092 | $9K | |
| 84100 | <1% | 10,807 | $9K | |
| 82950 | <1% | 3,017 | $8K | |
| 85730 | <1% | 8,786 | $8K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 12 | $8K |
| 80055 | <1% | 331 | $8K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 680 | $8K |
| 83516 | <1% | 723 | $8K | |
| 82248 | <1% | 5,578 | $8K | |
| 83020 | <1% | 1,284 | $8K | |
| 0012A | <1% | 214 | $7K | |
| 86039 | <1% | 1,328 | $7K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 5,697 | $7K |
| 84153 | <1% | 641 | $7K | |
| 85652 | <1% | 5,659 | $7K | |
| 86140 | <1% | 3,754 | $7K | |
| 86787 | <1% | 1,144 | $7K | |
| 83615 | <1% | 3,276 | $7K | |
| 0011A | <1% | 236 | $7K | |
| 86364 | <1% | 592 | $7K | |
| 70491 | <1% | 66 | $7K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 970 | $6K |
| 87807 | <1% | 1,782 | $6K | |
| 88307 | <1% | 170 | $6K | |
| 82247 | <1% | 6,779 | $6K | |
| 80076 | <1% | 2,650 | $6K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 12 | $6K |
| 86696 | <1% | 600 | $6K | |
| 76820 | <1% | 13,296 | $6K | |
| 95811 | <1% | 12 | $6K | |
| 74019 | <1% | 851 | $5K | |
| 84156 | <1% | 3,645 | $5K | |
| 84550 | <1% | 2,460 | $5K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 241 | $5K |
| 83690 | <1% | 15,858 | $5K | |
| 70498 | <1% | 988 | $5K | |
| 86038 | <1% | 708 | $5K | |
| 86901 | <1% | 10,479 | $5K | |
| 96417 | <1% | 134 | $5K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,830 | $5K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 13 | $5K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 130 | $5K |
| 82677 | <1% | 456 | $5K | |
| 72040 | <1% | 268 | $5K | |
| 73221 | <1% | 37 | $4K | |
| 86431 | <1% | 1,430 | $4K | |
| 82550 | <1% | 2,929 | $4K | |
| 87205 | <1% | 2,724 | $4K | |
| 86695 | <1% | 599 | $4K | |
| 87522 | Neg quan hep c or qual rna | <1% | 237 | $4K |
| 86480 | <1% | 99 | $4K | |
| 96376 | <1% | 13,704 | $4K | |
| 82150 | <1% | 2,032 | $4K | |
| 86258 | <1% | 236 | $4K | |
| 92523 | <1% | 37 | $4K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 14 | $4K |
| 84144 | <1% | 356 | $3K | |
| 64400 | <1% | 28 | $3K | |
| 83721 | <1% | 508 | $3K | |
| 81003 | <1% | 7,769 | $3K | |
| 82731 | <1% | 209 | $3K | |
| 97166 | <1% | 68 | $3K | |
| 82652 | <1% | 141 | $3K | |
| 86336 | <1% | 457 | $3K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,162 | $3K |
| 93880 | <1% | 43 | $3K | |
| 86706 | <1% | 502 | $3K | |
| 0352U | <1% | 849 | $3K | |
| 84075 | <1% | 4,937 | $3K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 27 | $3K |
| 87529 | <1% | 103 | $3K | |
| 87400 | <1% | 3,793 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 264 | $3K |
| 90686 | <1% | 156 | $3K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 36 | $3K |
| 86225 | <1% | 330 | $3K | |
| 71101 | <1% | 222 | $2K | |
| 86376 | <1% | 238 | $2K | |
| 84402 | <1% | 157 | $2K | |
| 82310 | <1% | 3,143 | $2K | |
| 82040 | <1% | 1,673 | $2K | |
| 86200 | <1% | 288 | $2K | |
| 97116 | <1% | 556 | $2K | |
| 84484 | <1% | 21,561 | $2K | |
| 74022 | <1% | 3,115 | $2K | |
| 73560 | <1% | 286 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 25,118 | $2K |
| 85007 | <1% | 1,625 | $2K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 118 | $2K |
| 84703 | <1% | 2,460 | $2K | |
| 85379 | <1% | 3,924 | $2K | |
| 73590 | <1% | 689 | $2K | |
| 76870 | <1% | 94 | $1K | |
| 81025 | <1% | 7,885 | $1K | |
| 86694 | <1% | 249 | $1K | |
| 86665 | <1% | 112 | $1K | |
| 97032 | <1% | 218 | $1K | |
| 85045 | <1% | 704 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 87 | $1K |
| 82747 | <1% | 120 | $1K | |
| 82378 | <1% | 120 | $1K | |
| 72170 | <1% | 181 | $1K | |
| 83090 | <1% | 154 | $1K | |
| 87634 | <1% | 24 | $1K | |
| 73080 | <1% | 267 | $1K | |
| 87040 | <1% | 4,002 | $1K | |
| 87631 | <1% | 12 | $1K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 85 | $1K |
| 99219 | <1% | 13 | $981.98 | |
| 92586 | <1% | 13 | $972.06 | |
| 80164 | <1% | 491 | $937.77 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 15 | $930.21 |
| 86304 | <1% | 80 | $905.71 | |
| 86800 | <1% | 94 | $881.79 | |
| 74174 | <1% | 12 | $859.91 | |
| 0004A | <1% | 27 | $847.77 | |
| 87521 | Neg quan hep c or qual rna | <1% | 40 | $842.38 |
| 87536 | <1% | 17 | $757.14 | |
| 73090 | <1% | 343 | $723.58 | |
| 82374 | <1% | 2,549 | $701.14 | |
| 81015 | <1% | 438 | $697.46 | |
| 84295 | <1% | 2,562 | $681.27 | |
| 82435 | <1% | 2,534 | $659.35 | |
| 93976 | <1% | 13 | $653.10 | |
| 84155 | <1% | 799 | $590.85 | |
| 82533 | <1% | 80 | $580.09 | |
| 70360 | <1% | 62 | $559.90 | |
| 86664 | <1% | 98 | $541.32 | |
| 83605 | <1% | 4,022 | $531.54 | |
| 83013 | <1% | 14 | $510.81 | |
| 84480 | <1% | 95 | $502.95 | |
| 86663 | <1% | 98 | $470.77 | |
| 86147 | <1% | 13 | $450.10 | |
| 84165 | <1% | 74 | $432.51 | |
| 84436 | <1% | 218 | $426.97 | |
| 87075 | <1% | 173 | $415.27 | |
| 72128 | <1% | 12 | $400.76 | |
| 90656 | <1% | 19 | $391.17 | |
| 86141 | <1% | 67 | $381.32 | |
| 86765 | <1% | 95 | $380.44 | |
| 86160 | <1% | 27 | $335.74 | |
| 76827 | <1% | 15 | $333.12 | |
| 83525 | <1% | 55 | $332.65 | |
| 82951 | <1% | 41 | $317.07 | |
| 87899 | <1% | 32 | $315.17 | |
| 84132 | <1% | 1,319 | $292.84 | |
| 72080 | <1% | 15 | $269.11 | |
| G0008 | Administration of influenza virus vaccine | <1% | 45 | $260.40 |
| 87498 | <1% | 12 | $247.93 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 637 | $243.20 |
| 76937 | <1% | 817 | $233.12 | |
| 83521 | <1% | 12 | $228.14 | |
| 86923 | <1% | 42 | $206.67 | |
| 80177 | <1% | 41 | $194.98 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,156 | $189.99 |
| 86735 | <1% | 73 | $189.43 | |
| 87046 | <1% | 27 | $189.03 | |
| 86300 | <1% | 13 | $184.68 | |
| 72072 | <1% | 12 | $166.62 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 38 | $160.79 |
| 84163 | <1% | 29 | $150.17 | |
| 86334 | <1% | 12 | $141.96 | |
| 82274 | <1% | 12 | $134.49 | |
| 86308 | <1% | 135 | $131.03 | |
| 88311 | <1% | 60 | $124.81 | |
| 99152 | <1% | 42 | $109.00 | |
| 85018 | <1% | 137 | $108.80 | |
| 86301 | <1% | 13 | $108.14 | |
| 72220 | <1% | 52 | $106.88 | |
| 84145 | <1% | 205 | $101.71 | |
| 76376 | <1% | 50 | $96.50 | |
| 87045 | <1% | 28 | $94.52 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,971 | $87.80 |
| 83520 | <1% | 1,243 | $84.00 | |
| 12001 | <1% | 684 | $78.05 | |
| 82952 | <1% | 29 | $77.53 | |
| 12011 | <1% | 178 | $64.58 | |
| 87015 | <1% | 14 | $64.46 | |
| 93922 | <1% | 12 | $53.99 | |
| 82140 | <1% | 44 | $47.63 | |
| 85651 | <1% | 79 | $43.03 | |
| 87449 | <1% | 29 | $33.54 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 370 | $32.73 |
| C1769 | Guide wire | <1% | 951 | $32.73 |
| 85014 | <1% | 40 | $32.05 | |
| 80178 | <1% | 15 | $31.11 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,143 | $26.81 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 20,976 | $23.02 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 295 | $20.64 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,869 | $19.62 |
| 84300 | <1% | 13 | $17.92 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 437 | $17.43 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 28 | $17.03 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,002 | $10.50 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 8,430 | $10.36 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 960 | $9.65 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,184 | $6.12 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,076 | $5.26 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 527 | $4.50 |
| J2704 | Injection, propofol, 10 mg | <1% | 8,719 | $4.12 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,774 | $1.92 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,118 | $1.90 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,169 | $1.15 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,246 | $0.99 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 20 | $0.41 |
| J1815 | Injection, insulin, per 5 units | <1% | 998 | $0.20 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 1,984 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 1,753 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 234 | $0.00 |
| 90715 | 0% | 1,372 | $0.00 | |
| 93356 | 0% | 1,237 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 7,119 | $0.00 |
| 90714 | 0% | 187 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 386 | $0.00 |
| 93325 | 0% | 252 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 1,004 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 456 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 441 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 114 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 306 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 125 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 171 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 41 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 90 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 45 | $0.00 |
| 91300 | 0% | 68 | $0.00 | |
| 99053 | 0% | 28 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 13 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 17 | $0.00 |
| 82010 | 0% | 16 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 2,573 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 4,704 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 7,085 | $0.00 |
| J3490 | Unclassified drugs | 0% | 3,954 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 4,494 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 4,191 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 231 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 3,016 | $0.00 |
| 93320 | 0% | 14 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 103 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 85 | $0.00 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 255 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 238 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 1,199 | $0.00 |
| A4351 | Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, or silicone elastomer, etc.), each | 0% | 43 | $0.00 |
| 94760 | 0% | 246 | $0.00 | |
| 36410 | 0% | 529 | $0.00 | |
| 12002 | 0% | 66 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 1,018 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 308 | $0.00 |
| 36416 | 0% | 477 | $0.00 | |
| 82553 | 0% | 203 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 535 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 48 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 57 | $0.00 |
| A9270 | Non-covered item or service | 0% | 2,307 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 25 | $0.00 |
| 92567 | 0% | 12 | $0.00 | |
| A4344 | Indwelling catheter, foley type, two-way, all silicone or polyurethane, each | 0% | 12 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 118 | $0.00 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 24 | $0.00 |
| 0399T | 0% | 39 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 52 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 46 | $0.00 |
| 80320 | 0% | 40 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGUSHO, MICHAEL (CFO)
Parent organizationTRINITY HEALTH MICHIGAN
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.